Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Early detection of increased thrombosis risk: New antithrombin test by Siemens Healthcare for the European markets

29.01.2009
Siemens Healthcare has developed Innovance Antithrombin, a new test for determining congenital and acquired antithrombin deficiency. Insufficient levels of protein in blood can lead to increased thrombophilia.

Reason: Antithrombin ensures balanced blood coagulation by reducing the activity of thrombin and coagulation factor Xa which are responsible for blood coagulation. Innovance Antithrombin detects insufficient antithrombin activity, enabling the early detection of an increased risk of thrombosis in patients.

Innovance Antithrombin by Siemens Healthcare is a new chromogenic test for the automatic quantification of functionally active antithrombin in human citrated plasma. In contrast to antithrombin activity tests based on the inhibition of the coagulation factor thrombin, Innovance Antithrombin determines the activity of the antithrombin protein through the inhibition of coagulation factor Xa. This prevents distortion of the test result if a patient was given specific medication to prevent or treat thromboses, such as hirudin or other thrombin inhibitors.

Innovance Antithrombin can be used with the automatic coagulation measuring devices from Siemens such as BCS and BCS XP as well as Sysmex CA-500, Sysmex CA-1500 and Sysmex CA-7000.

The new test by Siemens is also suitable for diagnosing congenital or acquired antithrombin deficiencies which are known to be linked with an increased risk of thrombosis. Antithrombin deficiencies manifest themselves in reduced activity of the antithrombin protein. Two types of congenital antithrombin deficiencies are distinguished: in case of deficiency type I, the total quantity of existing antithrombin protein is reduced, whereas in case of deficiency type II, the protein concentration is normal, but the protein is defective in respect of its inhibitor function.

Acquired antithrombin deficiency exists if less antithrombin protein is produced or more is spent than usual. This may result, for example, from liver diseases, DIC (disseminated intravascular coagulation), sepsis, acute hemolytic transfusion reaction, nephrotic syndrome or major surgical interventions. The test can also serve for monitoring the substitution therapy with antithrombin concentrates.

The test kit components of Innovance Antithrombin are ready for use and therefore especially fast and easy to use. The test is based on a chromogenic measurement principle. Citrated plasma is mixed with a surplus of coagulation factor Xa. If heparin is present, part of coagulation factor Xa is bonded and deactivated by the antithrombin present in the specimen. Surplus, uninhibited coagulation factor Xa then splits a chromogenic substrate. In this process, coloring is released, the concentration of which is detected with a photometer.

The higher the concentration of the produced coloring, the higher was the quantity of uninhibited coagulation factor Xa and the lower was the concentration of functionally active antithrombin originally present in the plasma specimen.

The Siemens Healthcare Sector is one of the world’s largest healthcare solution providers. The company defines itself as a medical solution provider with core competences and innovative strengths in diagnostic and therapeutic technologies as well as knowledge processing, including information technology and system integration. With its acquisitions in laboratory diagnostics, Siemens Healthcare is the first integrated healthcare company that combines imaging and lab diagnostics, therapy solutions and medical information technology and also supplements these with consultation and services. Siemens Healthcare provides solutions for the entire supply chain under one umbrella – from prevention, early detection and diagnosis to therapy and aftercare. In addition, Siemens Healthcare is the global brand leader for innovative hearing aids. Siemens Healthcare currently has around 49,000 employees worldwide and is represented in more than 130 countries. During fiscal 2008 (ending on September 30), Siemens Healthcare achieved a total sales volume of 11.17 billion euros and incoming orders totaling 11.78 billion euros. The Group earnings amounted to 1.23 billion euros.

Marion Bludszuweit | Siemens Healthcare
Further information:
http://www.siemens.com/healthcare

More articles from Medical Engineering:

nachricht Heart examinations: Miniature particle accelerator saves on contrast agents
27.02.2017 | Technische Universität München

nachricht Novel breast tomosynthesis technique reduces screening recall rate
21.02.2017 | Radiological Society of North America

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

Sandia uses confined nanoparticles to improve hydrogen storage materials performance

27.02.2017 | Interdisciplinary Research

Decoding the genome's cryptic language

27.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>